Holen Sie sich die Stockscreener-App
28.80
6.19%
1.68
Handel nachbörslich:
28.80
Schlusskurs vom Vortag:
$27.12
Offen:
$27.46
24-Stunden-Volumen:
1.73M
Relative Volume:
2.24
Marktkapitalisierung:
$1.46B
Einnahmen:
$534.53M
Nettoeinkommen (Verlust:
$-11.45M
KGV:
-119.45
EPS:
-0.2411
Netto-Cashflow:
$48.28M
1W Leistung:
+1.37%
1M Leistung:
+1.12%
6M Leistung:
-28.71%
1J Leistung:
-8.89%
1-Tages-Spanne:
$27.43
$29.03
1-Wochen-Bereich:
$26.81
$29.14
52-Wochen-Spanne:
$25.36
$43.18
Atricure Inc Stock (ATRC) Company Profile
Firmenname
Atricure Inc
Sektor
Telefon
513-755-4100
Adresse
7555 INNOVATION WAY, MASON, OH
Compare ATRC vs ISRG, BDX, ALC, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRC
Atricure Inc
|
28.80 | 1.46B | 534.53M | -11.45M | 48.28M | -0.2411 |
ISRG
Intuitive Surgical Inc
|
406.78 | 144.07B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
143.98 | 39.67B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
64.68 | 31.54B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
35.94 | 30.39B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
188.63 | 27.36B | 5.54B | 1.52B | 1.74B | 10.37 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2026-02-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-12-17 | Fortgesetzt | JP Morgan | Overweight |
| 2024-04-23 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-23 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-09-29 | Eingeleitet | UBS | Buy |
| 2021-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-12-18 | Bestätigt | Needham | Buy |
| 2020-11-06 | Bestätigt | Needham | Buy |
| 2020-04-07 | Eingeleitet | Oppenheimer | Outperform |
| 2020-02-06 | Eingeleitet | BTIG Research | Buy |
| 2020-01-24 | Bestätigt | Needham | Buy |
| 2019-08-13 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-04-12 | Eingeleitet | JP Morgan | Overweight |
| 2018-10-04 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Stifel | Buy |
| 2018-06-18 | Bestätigt | Needham | Buy |
| 2018-04-27 | Bestätigt | Needham | Buy |
| 2018-01-16 | Bestätigt | Needham | Buy |
| 2017-11-02 | Bestätigt | Needham | Buy |
| 2017-07-28 | Bestätigt | Needham | Buy |
| 2017-05-30 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-06-30 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2015-10-28 | Bestätigt | Needham | Buy |
| 2015-10-06 | Bestätigt | Canaccord Genuity | Buy |
| 2015-10-06 | Bestätigt | Needham | Buy |
Alle ansehen
Atricure Inc Aktie (ATRC) Neueste Nachrichten
AtriCure (ATRC) Soars 6.2%: Is Further Upside Left in the Stock? - Yahoo Finance
AtriCure Inc (ATRC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
AtriCure Inc (ATRC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AtriCure Inc (ATRC) Valuation: PE, PB & Fair Value Analysis - TradingKey
AtriCure Inc (ATRC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AtriCure Inc (ATRC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AtriCure Inc (ATRC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AtriCure Inc (ATRC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
AtriCure Inc (ATRC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Trading Systems Reacting to (ATRC) Volatility - Stock Traders Daily
Do options traders know something about AtriCure stock we don't? - MSN
AtriCure (ATRC) Q1 2026 Earnings Transcript - AOL.com
Do Options Traders Know Something About AtriCure Stock We Don't? - Yahoo Finance
A Look At AtriCure (ATRC) Valuation As BoxX NoAF Trial Acceleration Draws Investor Attention - Yahoo Finance
How Investors May Respond To AtriCure (ATRC) Accelerating BoxX-NoAF Trial Enrollment And Q1 2026 Momentum - Sahm
AtriCure faces market doubts despite revenue growth; share prices fall. Insider optimism hints at potential turnaround, but long-term earnings are the focus. - Moomoo
AtriCure (ATRC) Advances Key Heart Disease Trial 12 Months Ahead of Schedule - Insider Monkey
AtriCure, Inc. Hits 52-Week Low at USD 25.37 Amid Market Struggles - Markets Mojo
AtriCure stock hits 52-week low at 25.51 USD By Investing.com - Investing.com Australia
AtriCure stock hits 52-week low at 25.51 USD - Investing.com
Top 10 Small Cap Stocks With Huge Growth Potential - Insider Monkey
AtriCure Inc. (ATRC) Slips 1.5% as Stock Hovers Near Key Support at $26.29Chart Pattern Alerts - The Legal Advocate
AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference - Yahoo Finance
Insider Sell Alert: Karen Prange Sells 3,000 Shares of AtriCure Inc (ATRC) - GuruFocus
(ATRC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
AtriCure director Karen Prange sells $85,950 in company stock By Investing.com - Investing.com Canada
AtriCure director Karen Prange sells $85,950 in company stock - Investing.com
AtriCure (ATRC) director Prange sells 3,000 shares, keeps 26,373 - Stock Titan
Director Karen Prange granted 6,144 AtriCure (ATRC) shares - Stock Titan
AtriCure (ATRC) director Deborah Telman awarded 6,144 restricted shares - Stock Titan
AtriCure (ATRC) director Maggie Yuen receives 6,144-share restricted stock award - Stock Titan
Director Nachman Shlomo receives 6,144 AtriCure (ATRC) restricted shares - Stock Titan
Director Kristine Johnson receives 6,144-share grant at AtriCure (ATRC) - Stock Titan
AtriCure (ATRC) director Regina Groves receives 6,144-share restricted stock grant - Stock Titan
AtriCure (ATRC) director Sven Wehrwein receives 6,144-share restricted stock grant - Stock Titan
Director at AtriCure (ATRC) receives 6,144-share restricted stock grant - Stock Titan
[144] AtriCure, Inc. SEC Filing - Stock Titan
AtriCure Shareholders Approve Expanded Equity and Governance Plans - TipRanks
AtriCure (ATRC) stockholders back equity plan share increases and director slate - Stock Titan
AtriCure conference: New devices, EnCompass drive 2026 growth outlook - MSN
Insider Sell: Vinayak Doraiswamy Sells 5,000 Shares of AtriCure Inc (ATRC) - GuruFocus
AtriCure (ATRC) Chief Scientific Officer sells 5,000 shares at $28.13 - Stock Titan
AtriCure Inc Annual Shareholders Meeting Transcript - GuruFocus
How AtriCure scaled legal operations with Thomson Reuters - Thomson Reuters Legal Solutions
Loss-Making AtriCure, Inc. (NASDAQ:ATRC) Set To Breakeven - Moomoo
ATRC (NASDAQ: ATRC) Form 144 shows 5,000-share sale and planned award disposals - Stock Titan
Wellington Management holds 3,382,555 ATRC shares (6.79%) — institutional stake - Stock Titan
AtriCure Inc (ATRC) Shares Surge 5.8% -- What GF Score of 79 Tel - GuruFocus
Finanzdaten der Atricure Inc-Aktie (ATRC)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):